Drug Trial Radar · NCT00873119
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Last checked: Nov 19, 2026Latest source record: Jul 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Feb 2009
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Valerio TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Spectrum Pharmaceuticals, Inc
- First posted
- Apr 1, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
Conditions
- Carcinoma of Unknown Primary
Interventions
belinostat, carboplatin, paclitaxelDrug
carboplatin, paclitaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: Tumor assessment every 6 weeks for the treatment period. Subsequent assessments every 6 weeks for the initial 6 months, then every 9 weeks for 6 months, then every 12 weeks for 12 months and then every 6 months until 5 years from the start of study
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists
Fort Myers, Florida
Northwest Georgia Oncology Centers
Marietta, Georgia
Baton Rouge Medical Center
Baton Rouge, Louisiana
Center for Cancers and Blood Disorders
Bethesda, Maryland
Research Medical Center
Kansas City, Missouri
Oncology Hematology Care Inc.
Cincinnati, Ohio
South Carolina Oncology Associates
Columbia, South Carolina
Chattanooga Oncology & Hematology Associates, PC
Chattanooga, Tennessee
Tennessee Oncology Sarah Cannon Research
Nashville, Tennessee
South Texas Oncology and Hematology
San Antonio, Texas
Virginia Cancer Institute
Richmond, Virginia
H:S Rigshospital, The Finsen Centre
Copenhagen, Denmark
CRLCC Francois Baclesse, Oncologie medicale
Caen, France
Centre Oscar Lambert
Lille, France
Centre Léon Bérard, Oncologie
Lyon, France
Centre Eugène Marquis
Rennes, France
Centre Henri Becquerel, Oncologie Médicale
Rouen, France
Institut de Cancerologie de la Loire
Saint-Priest-en-Jarez, France
Institut Gustave Roussy IGR
Villejuif, France
Carl-Gustav-Carus Medicinische Klinik und Poliklinik I
Dresden, Germany
Kliniken Essen-Mitte
Essen, Germany
ASKLEPIOS Klinik Altona
Hamburg, Germany
Ostholstein-Onkologie
Oldenburg in Holstein, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.